Drug Approval | August 27, 2022
Lupin receives UK MHRA Approval of Lutio for treatment of COPD
Lutio has the potential to offer significant cost savings when available to UK patients.
Lutio has the potential to offer significant cost savings when available to UK patients.
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
The entire integration and transition of the brands is expected to be completed by March 2022
Lupin has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
